Revival of interest in peptides as potential drug candidates because of their low oral bioavailability has been a major factor fuelling growth of the global peptide therapeutics market. Lack of oral efficacy in peptide drug delivery has actually helped researchers to find innovative methods of peptide drug delivery. However, there is still low acceptance among end users; hence creating awareness could open up opportunities in the market. Peptide therapeutics are used for treating prostrate, breast, ovarian and pancreatic cancers.
Market Value and Forecast
In 2014, the Peptide Therapeutics Market was valued at US$ 16,000.0 Mn and revenue is expected to expand at a CAGR of 10.3% over 2015-2025. This is attributed to advancements in the field of synthetic peptides and emergence of prominent biopharmaceutical companies, fuelled by an increase in prevalence of metabolic disorders.
Economic factors such as government policies for start-up companies in emerging economies, increasing FDI in emerging regions and increasing healthcare expenditure are expected to drive market growth globally. Increasing prevalence of cardiovascular & metabolic disorders, advancements in synthetic peptides, emergence of prominent pharmaceutical and biotech companies, high specificity of peptides leading to high clinical value, advanced & strong pipelines and patent expiries among others, are fuelling growth of the global peptide therapeutics market. However, various factors such as increasing commercialisation costs, oral bioavailability of peptide drugs and rapid metabolism and regulatory conditions for peptide drugs is expected to inhibit market growth.
Market Segmentation by Application Type
By application type, the global peptide therapeutics market is segmented into cancer, cardiovascular, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, endocrinology and other applications. The cancer application type segment accounts for highest market share currently, and is expected to remain the leading segment in terms of value during the forecast period.
Market Segmentation by Route Of Administration
In terms of route of administration segmentation, parenteral route of administration is expected to hold more than half the global market share, while revenue from the oral route of administration segment is projected to expand at the highest CAGR over the forecast period as compared to other segments.
Market Segmentation by Drug Type
By drug type segmentation, generic drug type segment is expected to register an exceptional CAGR during the forecast period owing to patent expiries of large number of branded drugs.
Request to view Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1038
On the basis of region, the market in North America currently holds highest share in the global market and the trend is expected to continue over the forecast period. Markets in the Americas and Europe have been estimated to collectively account for over 75% revenue share of the global peptide therapeutics market in 2015. MEA is projected to exhibit above average CAGR in terms of value between 2015 and 2025. The market in MEA is expected to gain a significant BPS over the forecast period, owing to an increase in prevalence of metabolic disorders, coupled with increasing number of pharmaceuticals companies in the region.
Key market players covered in this report are AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group and Teva Pharmaceutical Industries Ltd.